**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      8-K**

**CURRENT      REPORT**

**Pursuant      to Section 13 or 15(d) of the Securities Exchange Act of      1934**

| Date                of Report (Date of earliest event reported) |   | March                15, 2007 |
|-----------------------------------------------------------------|--------|-------------------------------|
|                                                            |   |                          |

| **Progenics                Pharmaceuticals, Inc.**                                   |
|--------------------------------------------------------------------------------------|
| (Exact                name of registrant as specified in its                charter) |

| **Delaware**                                                                |   | **000-23143**                          |   | **13-3379479**                                                 |   |
|-----------------------------------------------------------------------------|--------|----------------------------------------|--------|----------------------------------------------------------------|--------|
| (State                or other jurisdictionof                incorporation) |   | (CommissionFile                Number) |   | (IRS                EmployerIdentification                No.) |   |

| **777                Old Saw Mill River Road, Tarrytown, New York** | **10591**                                                                                                                                    |   |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------|
| (Address                of principal executive offices)             |                                    (Zip Code) |   |

| Registrant's                telephone number, including area code | **(914)                789-2800** |   |
|-------------------------------------------------------------------|-----------------------------------|--------|

*see      *

| o       | Written                communications pursuant to Rule 425 under the Securities Act (17                CFR                230.425)                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                                                                                                                                |
|  o | Soliciting                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR                240.14a-12)                                |
|    |                                                                                                                                                |
|  o | Pre-commencement                communications pursuant to Rule 14d-2(b) under the Exchange Act (17                CFR                240.14d-2(b)) |
|    |                                                                                                                                                |
|  o | Pre-commencement                communications pursuant to Rule 13e-4(c) under the Exchange Act (17                CFR                240.13e-4(c)  |

----

**Item      2.02 Results of Operations and Financial Condition.**

**Item      9.01 Financial Statements and Exhibits.**

| **Exhibit                No.** |   | **Description**                                   |   |
|--------------------------------|--------|---------------------------------------------------|--------|
|                           |   |                                              |   |
| 99.1                           |   | Press                Release dated March 15, 2007 |   |

----

**SIGNATURES**

|   |   | **PROGENICS                PHARMACEUTICALS, INC.**                                                    |
|--------|--------|-------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                  |
|   | By:    | /s/                ROBERT                A.                MCKINNEY                                   |
|   |   | Robert                A. McKinney                                                                     |
|   |   | Chief                Financial Officer Senior Vice President, Finance &                Operations |